Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
GNE-493
227
CHF
CHF 227.00
In stock
SYN-1115-M0011 mgCHF 227.00
SYN-1115-M0055 mgCHF 461.00
SYN-1115-M01010 mgCHF 646.00
SYN-1115-M05050 mgCHF 1'646.00
SYN-1115-M100100 mgCHF 2'490.00

Product Details | |
---|---|
Synonyms | GNE493 |
Product Type | Chemical |
Properties | |
Formula | C17H20N6O2S |
MW | 372.4 |
CAS | 1033735-94-2 |
Purity Chemicals | ≥95% |
Appearance | Solid. |
Solubility | Soluble in DMSO. |
Declaration | Manufactured by SynKinase. |
Other Product Data |
Target: PI3K | Kinase Group: Lipid Kinase | Substrate: Lipid Click here for Original Manufacturer Product Datasheet Our product description may differ slightly from the original manufacturers product datasheet. |
InChi Key | LEXMMFPAPDGYGZ-UHFFFAOYSA-N |
Shipping and Handling | |
Shipping | AMBIENT |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
Documents | |
MSDS |
![]() |
Product Specification Sheet | |
Datasheet |
![]() |
GNE-493 is a potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitor for the treatment of cancer.
Product References
- Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer: D.P. Sutherlin, et al.; J. Med. Chem. 53, 1086 (2010)
- Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform: T.P. Heffron, et al.; J. Med. Chem. 54, 7815 (2011)